Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.36 |
| ▸ | CRACR2A | Q9BSW2 | 7/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25646885 | 0.98 | TLR8 (0.41) | TSHRPOLBTLR8PLATKDM4E | |
| SCHEMBL12672148 | 0.93 | TSHR (0.45) | TSHRPOLBPLATKDM4EALDH1A1 | |
| SCHEMBL5214306 | 0.85 | PLAT (0.54) | TSHRPOLBPLAT | |
| SCHEMBL25276981 | 0.84 | PLAT (0.41) | TSHRPOLBPLATKDM4EALDH1A1 | |
| SCHEMBL25271935 | 0.79 | POLB (0.37) | TSHRPOLBPLATKDM4EALDH1A1 | |
| SCHEMBL20371631 | 0.79 | POLB (0.46) | TSHRPOLBTLR8PLATKDM4E | |
| SCHEMBL14555383 | 0.79 | MAP3K12 (0.43) | TSHRPOLBTLR8PLATKDM4E | |
| SCHEMBL25647007 | 0.78 | POLB (0.45) | TSHRPOLBTLR8PLATKDM4E | |
| SCHEMBL13093345 | 0.77 | KDM4E (0.44) | TSHRPOLBKDM4E | |
| SCHEMBL25647104 | 0.76 | NR3C2 (0.40) | TSHRPOLBTLR8PLATKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | TSHR 4824/4885POLB 1747/4885TLR8 2579/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | TSHR 4824/4885POLB 1747/4885TLR8 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.